Remove digital-detail
article thumbnail

Opinion: STAT+: Some countries are moving to digital prescription drug information for patients. The U.S. shouldn’t follow suit

STAT

Having all of these details in accessible, printed documents keeps patients informed and mitigates the risk of medication errors. Lawmakers seem to think that printed medication information is obsolete in the digital era and feel that using QR codes is an easy way to “go green.” ” The U.S.

article thumbnail

Is the pharmaceutical sector realising its potential for sustainable manufacturing?

European Pharmaceutical Review

Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. Credit: Siemens Plc The industry can reorder the process towards design-test-make by moving from the current model towards an R&D approach based heavily on detailed virtual modelling.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Digital Health Education for Health Professionals: What are the Next Steps?

The Digital Apothecary

I have served as an academic for the past eight years as an assistant and now associate professor of pharmacy practice, and during this time, my primary concern has been getting health professionals into digital health. How do we get Digital Health into Medical Education?

Inpatient 130
article thumbnail

Game changing: How AI and automation is revolutionising clinical trial admin 

Pharmaceutical Technology

Dan Herron, of digital offerings at RWS Life Sciences, details how AI and algorithms can be used to optimise these administrative processes.

52
article thumbnail

Health Innovators – Matt Dugan

pharmaphorum

Pharmaphorum Editor-in-Chief Jonah Comstock welcomes Matt Dugan, director and head of innovation at Novo Nordisk, to discuss the company’s digital transformation journey. The post Health Innovators – Matt Dugan appeared first on.

article thumbnail

EXCLUSIVE: The 340B Program Reached $54 Billion in 2022—Up 22% vs. 2021 (rerun)

Drug Channels

Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. Every 340B covered entity type experienced double-digit growth, despite drug prices that grew more slowly than overall inflation. Read on for full details and analysis, including the opportunity to download your own copy of the raw data from HRSA.

article thumbnail

Breathing easy: How digital inhalers are changing asthma treatment

Pharmaceutical Technology

AstraZeneca , Teva Pharmaceuticals , and Novartis , and other companies, are expanding their reach in the asthma space by capitalizing on digital technologies to enhance the patient experience. The use of digital inhalers has certainly grown,” says Chan. However, their use in routine healthcare is still limited,” adds Chan.